Hydroxychloroquine Shows Potential to Treat PPMS in Phase 2 Trial

Hydroxychloroquine Shows Potential to Treat PPMS in Phase 2 Trial

308560

Hydroxychloroquine Shows Potential to Treat PPMS in Phase 2 Trial

Treatment with hydroxychloroquine, an anti-malaria medication, appeared to help slow disability progression among people with primary-progressive multiple sclerosis (PPMS) in a small, proof-of-concept clinical trial. Hydroxychloroquine “is a promising treatment candidate for PPMS and should be investigated further in randomized controlled clinical trials,” its researchers wrote. Results of the study “Hydroxychloroquine for Primary Progressive Multiple Sclerosis,” were published in Annals of Neurology. PPMS is the rarest form of multiple sclerosis (MS), and it has historically been the…

You must be logged in to read/download the full post.